Cellectar Biosciences to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 2, 2023
- Cellectar Biosciences will report its financial results for Q3 2023 on November 2. They will also host a conference call to discuss financial results and provide an overview of the Waldenstrom’s macroglobulinemia market and their lead product candidate, iopofosine I 131.
- None.
FLORHAM PARK, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of targeted drugs for the treatment of cancer, today announced that the company will report its financial results for the three months ended September 30, 2023 on Thursday, November 2, 2023. Management will also host a conference call with investors to discuss financial results and provide an overview focused on the Waldenstrom’s macroglobulinemia market and its lead product candidate, iopofosine I 131, at 8:30 am Eastern Time. Details for the call are as follows:
| Conference call & Webcast Details: | |
| Date: | Thursday, November 2 |
| Time: | 8:30 am Eastern Time |
| Toll Free: | 1-888-886-7786 |
| International: | 1-416-764-8658 |
| Webcast: | Click HERE |
| Call me™: | Click HERE |
Participants may use the dial-in numbers above and be answered by an operator OR click Call me™ link for instant telephone access to the event. The Call me™ link will be made active 15 minutes prior to the scheduled start time.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
For more information, please visit www.cellectar.com and www.wmclinicaltrial.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.
Contacts
INVESTORS:
Monique Kosse
LifeSci Advisors
212-915-3820
monique@lifesciadvisors.com
MEDIA:
Claire LaCagnina
Bliss Bio Health
315-765-1462
clacagnina@blissbiohealth.com
FAQ
When will Cellectar Biosciences report its Q3 2023 financial results?
What will Cellectar Biosciences discuss during the conference call?
What is Cellectar Biosciences' ticker symbol?
What is Cellectar Biosciences focused on?
